{
  "benchmark_name": "Epigenetic and Signaling Crosstalk in Cardiac Fibrotic Remodeling (article)",
  "fact_edges": [
    [
      "CARDEX-1 / CDX1",
      "ACTIVATES_PHOSPHORYLATION_OF_(STIMULUS_DEPENDENT)",
      "PKN-δ2"
    ],
    [
      "PKN-δ2",
      "PART_OF",
      "TGFβ-CAR cascade"
    ],
    [
      "TGFβ-CAR cascade",
      "INDUCES_PHOSPHORYLATION_AND_NUCLEAR_TRANSLOCATION_OF",
      "SMADL-7"
    ],
    [
      "SMADL-7",
      "BINDS_PROMOTER_OF",
      "Fibrotic Transcriptional Program"
    ],
    [
      "SMADL-7",
      "UPREGULATES_TRANSCRIPTION_OF",
      "Fibrotic Transcriptional Program"
    ],
    [
      "Fibrotic Transcriptional Program",
      "ASSOCIATED_WITH_SEVERITY_OF_(META_ANALYSIS)",
      "Cardiac fibrotic syndrome"
    ],
    [
      "SILEN-β",
      "EXPRESSION_ASSOCIATED_WITH_RESISTANCE_TO",
      "Cardiac fibrotic syndrome"
    ],
    [
      "SILEN-β",
      "INCREASES_ACTIVITY_OF",
      "HDAC-9X"
    ],
    [
      "HDAC-9X",
      "REMOVES_ACETYLATION_ON",
      "Histone H3K27 acetylation"
    ],
    [
      "HDAC-9X",
      "UPREGULATES",
      "Epigenetic Repression Module"
    ],
    [
      "Epigenetic Repression Module",
      "OVERLAPS_WITH_(78%_INTERSECTION)_PROMOTER_REGIONS_OF",
      "Fibrotic Transcriptional Program"
    ],
    [
      "Epigenetic Repression Module",
      "INHIBITS_TRANSCRIPTION_OF",
      "Fibrotic Transcriptional Program"
    ],
    [
      "FBG-α",
      "PART_OF",
      "WNT-FIB loop"
    ],
    [
      "FBG-α",
      "SCAFFOLDS_RECRUITMENT_OF",
      "β-catenin"
    ],
    [
      "Wnt3a",
      "ACTIVATES",
      "Fibrotic Transcriptional Program"
    ],
    [
      "Wnt3a",
      "ACTIVATES_INDEPENDENT_OF",
      "TGFβ-CAR cascade"
    ],
    [
      "mTOR-MET branch",
      "REGULATES",
      "Metabolic Reprogramming Response"
    ],
    [
      "Metabolic Reprogramming Response",
      "ENTAILS_SUBSTRATE_SHIFT",
      "fatty_acid_oxidation_to_glycolysis"
    ],
    [
      "PKD2",
      "MODULATES_(IN_KIDNEY_TISSUE)",
      "mTOR-MET branch"
    ],
    [
      "PKD2",
      "NO_DEMONSTRATED_ROLE_IN",
      "mTOR-MET branch"
    ],
    [
      "Metabolic Reprogramming Response",
      "ASSOCIATED_WITH_PROGRESSION_OF_(CLINICAL_COHORTS)",
      "Cardiac fibrotic syndrome"
    ],
    [
      "Cardivex",
      "SELECTIVELY_INHIBITS_PHOSPHORYLATION_OF",
      "SMADL-7"
    ],
    [
      "Cardivex",
      "BINDS",
      "SMADL-7"
    ],
    [
      "Cardivex",
      "REDUCES_EXPRESSION_OF_(IC50_120_NM)",
      "Fibrotic Transcriptional Program"
    ],
    [
      "Silenor",
      "INCREASES_ACTIVITY_OF_(3.5_FOLD)",
      "HDAC-9X"
    ],
    [
      "Silenor",
      "UPREGULATES",
      "Epigenetic Repression Module"
    ],
    [
      "Silenor",
      "EFFECTS_MEDIATED_VIA",
      "HDAC-9X"
    ],
    [
      "Cardivex + Silenor (combination)",
      "ADDITIVE_REDUCTION_OF",
      "fibrotic markers"
    ],
    [
      "SILEN-β",
      "OVEREXPRESSION_REDUCES",
      "fibrotic markers"
    ],
    [
      "NOTCH-R3",
      "DETECTED_IN",
      "fibrotic cardiac tissue"
    ],
    [
      "NOTCH-R3",
      "NO_CONSISTENT_EFFECT_ON",
      "Fibrotic Transcriptional Program"
    ]
  ],
  "derived_edges": [
    [
      "CARDEX-1 / CDX1",
      "INDIRECTLY_INCREASES_VIA_MULTI_STEP_CHAIN",
      "Fibrotic Transcriptional Program"
    ],
    [
      "CARDEX-1 / CDX1",
      "INDIRECTLY_INFLUENCES",
      "Cardiac fibrotic syndrome"
    ],
    [
      "Epigenetic Repression Module",
      "INDIRECTLY_REDUCES_VIA_FTP_INHIBITION",
      "Cardiac fibrotic syndrome"
    ],
    [
      "HDAC-9X",
      "ACTIVATION_PREDICTED_TO_REDUCE",
      "Cardiac fibrotic syndrome"
    ],
    [
      "SILEN-β",
      "PROTECTIVE_EFFECT_VALIDATED_IN_ORGANOIDS_REDUCES",
      "Cardiac fibrotic syndrome"
    ],
    [
      "Cardivex + Silenor (combination)",
      "PREDICTED_TO_ENHANCE_REDUCTION_OF",
      "Cardiac fibrotic syndrome"
    ]
  ],
  "contradicted_edges": [
    [
      "CARDEX-1 / CDX1",
      "DIRECTLY_ASSOCIATED_WITH",
      "Cardiac fibrotic syndrome"
    ],
    [
      "HDAC-9X",
      "UPREGULATES",
      "Fibrotic Transcriptional Program"
    ],
    [
      "PKN-δ2",
      "MODULATES",
      "mTOR-MET branch"
    ],
    [
      "NOTCH-R3",
      "INFLUENCES",
      "Cardiac fibrotic syndrome"
    ],
    [
      "NOTCH-R3",
      "INFLUENCES",
      "Fibrotic Transcriptional Program"
    ]
  ],
  "hypothesis_only": [
    [
      "FBG-α",
      "MAY_INFLUENCE",
      "Epigenetic Repression Module"
    ],
    [
      "mTOR-MET branch",
      "MAY_DIRECTLY_INFLUENCE",
      "Fibrotic Transcriptional Program"
    ],
    [
      "rapamycin",
      "PRODUCED_NON_SIGNIFICANT_TREND_TOWARD_REDUCING",
      "Fibrotic Transcriptional Program"
    ]
  ],
  "entities": {
    "Cardiac fibrotic syndrome": {
      "type": "DISEASE",
      "aliases": [
        "CFS",
        "fibrotic cardiomyopathy"
      ],
      "note": "Clinical syndrome characterized by extracellular matrix deposition and cardiomyocyte loss."
    },
    "Fibrotic Transcriptional Program": {
      "type": "TRANSCRIPTIONAL_PROGRAM",
      "aliases": [
        "FTP",
        "fibrotic program",
        "fibrotic gene module"
      ],
      "note": "Coordinated gene expression program driving fibrotic remodeling."
    },
    "CARDEX-1 / CDX1": {
      "type": "GENE_PROTEIN",
      "aliases": [
        "CARDEX-1",
        "CDX1",
        "the cardiogenic regulator"
      ],
      "note": "Cardiogenic factor studied as upstream regulator of TGFβ-CAR axis."
    },
    "PKN-δ2": {
      "type": "KINASE",
      "aliases": [
        "PKNd2",
        "delta-2 kinase"
      ],
      "note": "Serine/threonine kinase; part of the TGFβ-CAR signaling assembly in cardiac cells."
    },
    "PKD2": {
      "type": "ION_CHANNEL",
      "aliases": [
        "polycystin-2"
      ],
      "note": "Calcium-permeable channel; structurally unrelated to PKN-δ2; shown to modulate mTOR-MET in kidney but not demonstrated in heart."
    },
    "TGFβ-CAR cascade": {
      "type": "PATHWAY",
      "aliases": [
        "T-CAR axis",
        "cardiac TGF module"
      ],
      "note": "Cardiogenic TGFβ-related signaling axis implicated in FTP activation."
    },
    "SMADL-7": {
      "type": "TRANSCRIPTIONAL_EFFECTOR",
      "aliases": [
        "SL7",
        "SMAD-like effector 7"
      ],
      "note": "Effector that is phosphorylated and translocates to nucleus to regulate FTP loci."
    },
    "SILEN-β": {
      "type": "GENE_PROTEIN",
      "aliases": [
        "SLNβ",
        "the β-silencer",
        "silencing gene beta"
      ],
      "note": "Epigenetic regulator highly expressed in fibrosis-resistant cardiac tissue."
    },
    "HDAC-9X": {
      "type": "ENZYME_(HISTONE_DEACETYLASE)",
      "aliases": [
        "H9X",
        "histone modifier 9X"
      ],
      "note": "Class II histone deacetylase that removes H3K27 acetylation and establishes ERM in cardiac cells."
    },
    "Epigenetic Repression Module": {
      "type": "EPIGENETIC_MODULE",
      "aliases": [
        "ERM",
        "chromatin silencing signature",
        "repression module"
      ],
      "note": "Chromatin state defined by H3K27 deacetylation at FTP loci; suppresses FTP transcription."
    },
    "FBG-α": {
      "type": "TRANSCRIPTION_FACTOR",
      "aliases": [
        "FBGα",
        "FBGA",
        "fibrogenic transcription factor"
      ],
      "note": "Component of WNT-FIB loop; scaffold for β-catenin recruitment."
    },
    "Wnt3a": {
      "type": "LIGAND",
      "note": "WNT ligand used experimentally to stimulate the WNT-FIB circuit."
    },
    "WNT-FIB loop": {
      "type": "PATHWAY",
      "aliases": [
        "W-F circuit",
        "Wnt-fibrotic signaling",
        "canonical WNT-fibrotic loop"
      ],
      "note": "WNT-dependent pro-fibrotic signaling axis active in cardiac fibroblasts."
    },
    "mTOR-MET branch": {
      "type": "PATHWAY",
      "aliases": [
        "M-branch",
        "metabolic mTOR module",
        "the metabolic arm"
      ],
      "note": "Metabolic signaling axis governing adaptation in stressed cardiomyocytes."
    },
    "Metabolic Reprogramming Response": {
      "type": "TRANSCRIPTIONAL_PROGRAM",
      "aliases": [
        "MRR",
        "metabolic shift signature",
        "the reprogramming response"
      ],
      "note": "Program of metabolic changes (FAO→glycolysis) regulated by mTOR-MET."
    },
    "Histone H3K27 acetylation": {
      "type": "EPIGENETIC_MARK",
      "aliases": [
        "H3K27ac"
      ],
      "note": "Acetylation mark removed by HDAC-9X to induce chromatin compaction."
    },
    "Cardiac Fibrosis Index": {
      "type": "CLINICAL_MEASURE",
      "aliases": [
        "CFI"
      ],
      "note": "Metric used to quantify CFS severity in cohorts."
    },
    "CardioGenomics Consortium GWAS (2024)": {
      "type": "STUDY",
      "aliases": [
        "CardioGenomics GWAS 2024"
      ],
      "note": "Large genome-wide association study reporting no association between CARDEX-1 variants and CFS."
    },
    "Cardivex": {
      "type": "DRUG",
      "aliases": [
        "CVX-12",
        "the antifibrotic agent"
      ],
      "note": "Small-molecule inhibitor that selectively blocks SMADL-7 phosphorylation (IC50 for FTP downregulation 120 nM)."
    },
    "Silenor": {
      "type": "DRUG",
      "aliases": [
        "SLR-8",
        "the chromatin modifier"
      ],
      "note": "Allosteric activator of HDAC-9X that increases H9X activity and upregulates ERM."
    },
    "rapamycin": {
      "type": "DRUG",
      "note": "mTOR inhibitor used to attenuate the M-branch in in vitro experiments (non-significant trend vs FTP)."
    },
    "NOTCH-R3": {
      "type": "PROTEIN",
      "note": "Detected in fibrotic tissue but shown experimentally to be a bystander with no consistent effects on FTP, ERM, or CFS phenotypes."
    },
    "fibrotic markers": {
      "type": "PHENOTYPE",
      "note": "Experimental readouts of fibrotic state (used in organoid and culture assays)."
    },
    "cardiomyocyte organoids": {
      "type": "EXPERIMENTAL_MODEL",
      "aliases": [
        "organoids"
      ],
      "note": "3D preclinical model used to validate SLNβ protective effect (40% reduction in fibrotic markers)."
    },
    "Cardivex + Silenor (combination)": {
      "type": "THERAPEUTIC_COMBINATION",
      "aliases": [
        "CVX-12 + SLR-8"
      ],
      "note": "Combined treatment produced additive reduction in fibrotic markers in preclinical models."
    }
  }
}
